{
    "clinical_study": {
        "@rank": "78961", 
        "arm_group": [
            {
                "arm_group_label": "Part A", 
                "arm_group_type": "Other", 
                "description": "Fimasartan (7 days) \u2192 Fimasartan + Rosuvastatin (7 days)"
            }, 
            {
                "arm_group_label": "Part B", 
                "arm_group_type": "Other", 
                "description": "Rosuvastatin (7 days) \u2192 Fimasartan + Rosuvastatin (7 days)"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase \u2160 study to evaluate the pharmacokinetic interactions and safety between fimasartan\n      and rosuvastatin in healthy male volunteers."
        }, 
        "brief_title": "To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "After subjects have signed informed consent voluntarily, they go through screening period\n      for within 21 days.\n\n      As period I, subjects of Part A take fimasartan for 7 days and subjects of Part B take\n      rosuvastatin for 7 days.\n\n      And then, after wash out for 7 days, as period II, subjects of both Part A and B take\n      fimasartan and rosuvastatin for 7 days.\n\n      At each period, subjects of Part A have blood sampling 2nd, 4th, 6th day before medication,\n      7th day before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48hour after\n      medication(17 times in each period, 34 times in total).\n\n      At each period, subjects of Part B have blood sampling 2nd, 4th, 6th day before medication,\n      7th day before and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 8, 12, 24, 48 and 72hour after\n      medication(17 times in each period, 34 times in total)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male subject, aged 20- 55 years at screening.\n\n          2. Body weight of \u2265 50 kg and within \u00b1 20% of ideal body weight (IBW)(kg) = {height (cm)\n             - 100} * 0.9\n\n          3. No abnormal symptom or sign, based on medical history and physical examination, with\n             no congenital or chronic disease that requires treatment\n\n          4. Subject that is considered appropriate for participating in the study by an\n             investigator, based on clinical laboratory test (serology, hematology, clinical\n             chemistry, urinalysis) and ECG, performed within 3 weeks prior to administration of\n             study drug\n\n          5. Subjects must be able to listen to and understand the detailed statement of informed\n             consent, and willing to decide to participate in the study, follow the study\n             directions and provide written informed consent\n\n        Exclusion Criteria:\n\n          1. History of clinically significant hypersensitivity to study drug, any other drug or\n             additives (yellow no.5).\n\n          2. History of any illness that may affect the absorption, distribution, metabolism or\n             excretion (hepatobiliary, renal, cardiovascular, endocrine (e.g., hypothyroidism),\n             respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric\n             and musculoskeletal system)\n\n          3. Hypotension (systolic \u2264 100 mmHg or diastolic \u2264 65 mmHg) or hypertension (systolic \u2265\n             140 mmHg or diastolic \u2265 90 mmHg), measured at screening\n\n          4. Active liver disease, or the levels of ALT(Aspartate Transaminase), AST (Alanin\n             Transaminase) or total bilirubin > 1.5 x the upper limit of normal\n\n          5. Creatinine clearance < 80 mL/min (calculated by Cockcroft-Gault formula using serum\n             creatinine)\n\n          6. Evidence of hereditary disease, including galactose intolerance, Lapp lactase\n             deficiency, or glucose-galactose malabsorption.\n\n          7. History of gastrointestinal disease (i.g., Crohn's disease, active peptic ulcer) or\n             resection operation that may affect the absorption of the study drug (excluding\n             simple appendectomy or herniorrhaphy)\n\n          8. History of major injury, surgical operation, or suspected symptom of acute illness\n             (severe infection, trauma, diarrhea or vomiting) within 4 weeks  prior to the first\n             administration of study drug\n\n          9. History of excessive alcohol abuse (>21 units/week, 1 unit=10g=12.5mL of pure\n             alcohol), or subjects who cannot abstain from drinking for at least 3 days prior to\n             the start of this study and throughout the study period, or excessive smoking (>10\n             cigarettes/day)\n\n         10. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any\n             over-the-counter medication within 1 week prior to the first administration of study\n             drug, and this will affect this study or the safety of the subjects in the opinion of\n             the investigator\n\n         11. Participation in any other study within 3 months  prior to the first administration\n             of study drug (The finish time of previous study is the day of the last\n             administration of study drug)\n\n         12. Donation of whole blood within 2 months prior to the first administration of study\n             drug, or donation of any blood products within 1 month prior to the first\n             administration of study drug\n\n         13. Abnormal diet that may affect absorption, distribution, metabolism and excretion of\n             drugs (*e.g., Grapefruit juice \u2265 1L /day within 7 days prior to administration of\n             study drug)\n\n         14. Positive serologic tests (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)\n\n         15. Subject that is judged inappropriate for participating in the study by an\n             investigator, based on clinical laboratory test (serology, hematology, clinical\n             chemistry, urinalysis) or any other reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921946", 
            "org_study_id": "BR-FMS-CT-116"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A", 
                    "Part B"
                ], 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A", 
                    "Part B"
                ], 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Fimasartan", 
        "lastchanged_date": "October 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of", 
                    "zip": "700-721"
                }, 
                "name": "Kyungpook National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase \u2160 Study to Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Kyungpook National University", 
            "last_name": "Young Ran Yoon, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "(AUC tau,ss),(Cmax,ss),(Cmin,ss), (Tmax,ss), (t1/2)", 
            "safety_issue": "Yes", 
            "time_frame": "0~72 hour after medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boryung Pharmaceutical Co., Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Kyungpook National University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Boryung Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}